Research Analysts’ upgrades for Wednesday, October 4th:

AMAG Pharmaceuticals (NASDAQ:AMAG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $21.00 target price on the stock. According to Zacks, “AMAG has been pursuing strategic acquisitions and deals to boost its portfolio and pipeline. The company is making its investments in the launch of Intrarosa, expansion of the label for Feraheme, development work to support the bremelanotide NDA and expected approval and launch of the Makena subcutaneous auto-injector (SQ) . In June 2017, the FDA accepted the sNDA for the Makena subcutaneous auto-injector. The agency has established a Prescription Drug User Fee Act (PDUFA) target action date of Feb 14, 2018. AMAG is focused on expanding the Makena’s label further in a bid to increase its market share. AMAG’s shares have underperformed the Medical-Biomedical/Genetics industry year to date.”

3D Systems Corporation (NYSE:DDD) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Over the past six months, 3D Systems’ shares have grossly underperformed the industry average. The company also has an extremely volatile earnings history, oscillating between strong beats and huge misses in the trailing four quarters. Adverse macroeconomic factors, such as slowdown, currency fluctuations and commodity prices, hurt the company’s performance. Escalating IT and go-to-market expenses remain headwinds, going forward. Nevertheless, its diverse technology portfolio enables it to offset weaknesses associated with a single product line. Going forward, strong demand for production printers, materials and software, as well as healthcare solutions will likely act as major catalysts for growth.We also believe the acquisition of Vertex-Global Holding B.V will unlock multiple opportunities for the billion-dollar digital dentistry space.”

DDR Corp. (NYSE:DDR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $10.00 price target on the stock. According to Zacks, “Shares of DDR have outperformed the industry it belongs to over the past three months. Encouragingly, the stock has seen the Zacks Consensus Estimate for 2017 and 2018 funds from operations (FFO) per share being revised upward in a month's time. The company recently completed its strategic planning and portfolio review process. With proceeds generated from disposition of assets and capital market access, it made progress on leverage reduction and lengthening of average debt maturity. Moreover, the company is focused on streamlining its organizational structure to enhance cost efficiency, centralize key operational decision making and improve bottom-line growth. However, the lackluster retail real estate market and the near-term earnings dilutive effects of divestitures remain concerns.”

GoPro (NASDAQ:GPRO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $12.00 target price on the stock. According to Zacks, “GoPro has been making company-wide restructuring efforts, which include a combination of programs to cut costs. GoPro’s revenues are growing, driven by robust sales of the latest Hero5 cameras, the re-launch of Karma and strong accessory sales. GoPro has been aiming towards transforming itself from the ‘camera maker’ to ‘content maker’, and has taken significant steps to diversify into higher-margin businesses including video editing and virtual reality. GoPro is also making strategic investments in talent, technology, software and innovative products for quite some time now. The company has also resumed Karma sales and plans to ramp production further. However, over the past one year, GoPro shares have significantly underperformed the industry’s average return. Multiple operational stumbles including product recalls, messed up launches, production delays and supply chain issues have added to the woes.”

Heroux Devtek (TSE:HRX) was upgraded by analysts at Raymond James Financial, Inc. from a market perform rating to an outperform rating. Raymond James Financial, Inc. currently has C$16.00 price target on the stock, up from their previous price target of C$13.00.

j2 Global (NASDAQ:JCOM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Shares of j2 Global have outperformed the industry it belongs to in a year. The company's growth-by-acquisition policy holds promise. It completed four acquisitions in the second quarter of 2017, spanning three business units and four countries. We are also impressed by the company's decision to hike its quarterly dividend payout by 2.7%. The company will now pay a dividend of 38.5  cents per share, which marks the 24th successive quarterly dividend hike. However, high costs have been hurting the company for quite some time and the third quarter is no different. We are also concerned about the company's high exposure to economic downturn as it has a vast majority of credit-sensitive customers. We are also cautious about the company's high debt levels.”

J d Wetherspoon Plc (OTC:JDWPY) was upgraded by analysts at Berenberg Bank from a sell rating to a hold rating.

Johnson & Johnson (NYSE:JNJ) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.  However, J&J is optimistic that sales growth will accelerate in 2H. We believe that new drugs like Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. However, J&J’s shares have underperformed the industry this year so far. Headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. Meanwhile, HCV sales continue to decline amid intense competition.  Estimates have remained mostly stable ahead of the Q3 results. J&J has a positive record of earnings surprises in recent quarters.”

Kennametal (NYSE:KMT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $46.00 target price on the stock. According to Zacks, “Year to date, Kennametal's shares have outperformed the industry. We believe that Kennametal holds solid organic and inorganic growth opportunities in the long term. Also, it aims at developing a sound cost structure by rationalization of certain manufacturing facilities and lowering of costs through employee and cost-reduction programs. By Dec 2018, cost savings are anticipated to be $165-$180 million. For fiscal 2018, the company anticipates adjusted earnings to be within $2.00-$2.30 per share, above $1.52 recorded in fiscal 2017. Organic revenue growth is expected to be within 2-4%. Over the last 60 days, earnings estimates on the stock increased for fiscal 2018.”

Momenta Pharmaceuticals (NASDAQ:MNTA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $20.00 price target on the stock. According to Zacks, “Momenta’s sales of Glatopa 20mg continue to do well and have captured approximately 40% of the market in the U.S. We are pleased with the company’s efforts to develop biosimilars given the potential in the market with recent approvals. In addition, a potential approval of M923 will boost investor confidence. The company has collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates. The progress with the autoimmune portfolio is also impressive However, the ANDA approval for Glatopa 40mg is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Shares of the company have outperformed the industry in the last twelve months.”

SOUTH32 LTD SPON (NASDAQ:SOUHY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $15.00 price target on the stock. According to Zacks, “South32 Limited is a resources company. The Company primarily produces alumina, aluminium, coal, manganese, nickel, silver, lead and zinc. South32 Limited is based in Perth, Australia. “

Splunk (NASDAQ:SPLK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $74.00 price target on the stock. According to Zacks, “Splunk Inc. provides a software platform, which collects and indexes data and enables users to search, correlate, analyze, monitor and report on this data, all in real time. Its software is designed to help users in various roles, including IT and business professionals. Splunk Inc. is based in San Francisco, California. “

Sequans Communications (NYSE:SQNS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Sequans Communications S.A., operates as a fabless designer, developer and supplier of 4G semiconductor solutions for wireless broadband applications. Solutions offered by the Company include baseband processor and radio frequency, or RF, transceiver integrated circuits, or ICs, along with signal processing techniques, algorithms and software stacks. Its solutions can be applied in devices like: smartphones; USB dongles; portable routers; embedded wireless modems for laptops, netbooks, tablets, and other consumer multimedia and industrial devices; consumer premises equipment, or CPE, such as residential gateways; and basestations. Sequans Communications S.A. is based in Paris, France. “

Spire (NYSE:SR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $84.00 price target on the stock. According to Zacks, “Spire Inc. is a public utility company which is engaged in the purchase, retail distribution, sale and marketing of natural gas. Its operating segment consists of Gas Utility and Gas Marketing. Gas Utility segment includes the regulated operations of Laclede Gas and Alabama Gas Corporation. Gas Marketing segment is engaged in the marketing of natural gas and related activities on a non-regulated basis. Spire Inc, formerly known as The Laclede Group Inc., is headquartered in St. Louis, Missouri. “

Shutterstock (NYSE:SSTK) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Shutterstock, Inc. is a global marketplace for digital imagery. It provides licensed photographs, vectors, illustrations and videos to businesses, marketing agencies and media organizations around the world. The Company’s online marketplace provides a freely searchable library of commercial digital images that the users can pay to license, download and incorporate into their work. Shutterstock, Inc. is headquartered in New York. “

Sierra Wireless (NASDAQ:SWIR) (TSE:SW) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Sierra Wireless, Inc. is a leading provider of wireless data communications products. The company delivers wireless PC Cards for portable computers, wireless adapters for PDA’s, OEM modules for embedded applications and rugged vehicle-mounted wireless systems. The company is the founding member of the WirelessReady Alliance, an alliance of industry-leading hardware, software and service companies committed to the delivery of complete and compelling wireless data solutions. “

TrueBlue (NYSE:TBI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “TRUEBLUE INC., headquartered in Tacoma, Wash., is the parent company of Labor Ready, Spartan Staffing, CLP Resources, and PlaneTechs. TrueBlue’s brands provide general labor, light industrial and skilled trades services to small to mid-sized businesses in the construction, warehousing, hospitality, landscaping, transportation, light manufacturing, retail, wholesale, facilities, sanitation, and aviation industries. “

Teladoc (NYSE:TDOC) was upgraded by analysts at Zacks Investment Research from a sell rating to a buy rating. Zacks Investment Research currently has $38.00 target price on the stock. According to Zacks, “The stock of Teladoc has outperformed the industry year to date. The company is witnessing steady business growth with insurers and customers increasingly embracing telehealth. It’s organic growth initiative remains on track. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. Its buyout of HealthiestYou has further strengthened its leadership position. Also the company boasts an impressive clientele. The company has also provided strong guidance for 2017.”

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Pricing erosion in the U.S. generics business and the continued deterioration in Venezuela is hurting sales at Teva which led to a guidance and dividend cut in August. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products and a high cost base and debt load. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Meanwhile, Teva is focusing on cost cutting and divestments to boost growth. However, a clear path to growth is not visible. Estimates have declined ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters.”

Teekay Corporation (NYSE:TK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $10.00 price target on the stock. According to Zacks, “Teekay Shipping Corporation is a leading provider of international crude oil and petroleum product transportation services through the world’s largest fleet of medium size oil tankers. The Company’s modern fleet provides such transportation services to major oil companies, major oil traders and government agencies, principally in the region spanning from the Red Sea to the U.S. West Coast. “

Tennant (NYSE:TNC) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Tennant Company, is a Minneapolis-based company that specializes in the design, manufacture, and sale of non-residential floor maintenance equipment and related products. The Company acquired the business and assets of Castex Industries, Inc., a privately owned manufacturer of commercial floor maintenance equipment. Products consisting mainly of motorized cleaning equipment and related products, including floor cleaning and preservation products, are sold through a direct sales organization and independent distributors. “

William Hil Adr (OTC:WIMHY) was upgraded by analysts at Berenberg Bank from a sell rating to a hold rating.

Receive News & Ratings for AMAG Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.